TY - JOUR
T1 - A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients
AU - Stadtmauer, Edward A.
AU - Sullivan, Keith M.
AU - Marty, Francisco M.
AU - Dadwal, Sanjeet S.
AU - Papanicolaou, Genovefa A.
AU - Shea, Thomas C.
AU - Mossad, Sherif B.
AU - Andreadis, Charalambos
AU - Young, Jo Anne H.
AU - Buadi, Francis K.
AU - Idrissi, Mohamed El
AU - Heineman, Thomas C.
AU - Berkowitz, Elchonon M.
N1 - Publisher Copyright:
© 2014 by The American Society of Hematology.
PY - 2014/11/6
Y1 - 2014/11/6
N2 - Recombinant herpes zoster (HZ) vaccines may be an alternative to the live-attenuated HZ vaccine for immunocompromised individuals. This was a phase 1/2, randomized, observer-blind, placebo-controlled study in adults with multiple myeloma, non-Hodgkin lymphoma (B- or T-cell), Hodgkin lymphoma, or acute myeloid leukemiawhohad undergone autologous hematopoietic stem-cell transplant 50 to 70 days earlier. Subjects (N = 121) were randomized 1:1:1:1 to receive (at months 0, 1, 3) three doses of 50 mg varicella-zoster virus glycoprotein E (gE) adjuvanted with AS01B, 3 doses of gE adjuvanted with AS01E, 1 dose of saline followed by 2 doses of gE/AS01B, or 3 doses of saline. One month after the last dose (6 months after transplant), frequencies of CD4+ T cells expressing ≥ activation markers after induction with gE and anti-gE antibody concentrations were higher with all gE/AS01 regimens than with saline. Both responses persisted up to 1 year in subjects vaccinated with gE/AS01. Immune responses were higher in the gE/AS01B 3-dose group than in the gE/AS01B 2-dose group but not higher than in the gE/AS01E 3-dose group. One serious adverse event (pneumonia) was considered vaccine related. Both formulations and both schedules were immunogenic and well tolerated in this population. This study was registered at www.clinicaltrials.gov as #NCT00920218.
AB - Recombinant herpes zoster (HZ) vaccines may be an alternative to the live-attenuated HZ vaccine for immunocompromised individuals. This was a phase 1/2, randomized, observer-blind, placebo-controlled study in adults with multiple myeloma, non-Hodgkin lymphoma (B- or T-cell), Hodgkin lymphoma, or acute myeloid leukemiawhohad undergone autologous hematopoietic stem-cell transplant 50 to 70 days earlier. Subjects (N = 121) were randomized 1:1:1:1 to receive (at months 0, 1, 3) three doses of 50 mg varicella-zoster virus glycoprotein E (gE) adjuvanted with AS01B, 3 doses of gE adjuvanted with AS01E, 1 dose of saline followed by 2 doses of gE/AS01B, or 3 doses of saline. One month after the last dose (6 months after transplant), frequencies of CD4+ T cells expressing ≥ activation markers after induction with gE and anti-gE antibody concentrations were higher with all gE/AS01 regimens than with saline. Both responses persisted up to 1 year in subjects vaccinated with gE/AS01. Immune responses were higher in the gE/AS01B 3-dose group than in the gE/AS01B 2-dose group but not higher than in the gE/AS01E 3-dose group. One serious adverse event (pneumonia) was considered vaccine related. Both formulations and both schedules were immunogenic and well tolerated in this population. This study was registered at www.clinicaltrials.gov as #NCT00920218.
UR - http://www.scopus.com/inward/record.url?scp=84909640008&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84909640008&partnerID=8YFLogxK
U2 - 10.1182/blood-2014-04-573048
DO - 10.1182/blood-2014-04-573048
M3 - Article
C2 - 25237196
AN - SCOPUS:84909640008
SN - 0006-4971
VL - 124
SP - 2921
EP - 2929
JO - Blood
JF - Blood
IS - 19
ER -
